Elarofiban is a potent, selective and orally active GPIIb/IIIa antagonist with an IC(50) of 0.4+/-0.3 nM. Elarofiban inhibits thrombin-induced platelet aggregation in human gel-filtered platelets (IC(50)=60+/-12 nM) and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, ADP, arachidonic acid, and SFLLRN-NH(2) (IC(50)=60+/-10, 70+/-4, 150+/-30, and 160+/-80 nM, respectively).

198958-88-2

C22H32N4O4

416.51

RWJ-53308;RWJ 53308;RWJ53308;Elarofiban

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years